Key result
Aspirin therapy increased in vitro platelet aggregation in response to PAF and ADP in 6 pregnant women at risk of or with pre-eclampsia, compared to baseline.
Why the study?
Does aspirin therapy alter in vitro platelet aggregation in pregnant women at risk of or with pre-eclampsia?
Observational (n=6)
No
Does aspirin therapy alter in vitro platelet aggregation in pregnant women at risk of or with pre-eclampsia?
Aspirin therapy in women at risk of pre-eclampsia increases in vitro platelet aggregation, suggesting a decrease in in vivo platelet activation and exhaustion.
May support reduced in vivo platelet activation with aspirin in pre-eclampsia; hypothesis-generating and should not yet change practice.
OBJECTIVE: To determine whether aspirin therapy in women at risk of pre-eclampsia alters in vitro platelet aggregation. DESIGN: Longitudinal observational study. SETTING: RPMS Institute of Obstetrics and Gynaecology, Hammersmith Hospital, London. SUBJECTS: Six pregnant women at-risk or with pre-eclampsia. METHODS: Women considered to be at risk of pre-eclampsia or with the disorder were treated with aspirin. In vitro platelet aggregation in response to platelet-activating factor (PAF) and adenosine diphosphate (ADP) before and after aspirin therapy were analysed. RESULTS: Prior to aspirin therapy platelet aggregation was decreased compared with normal pregnant women. After aspirin therapy platelet aggregation in response to PAF and ADP was greater, but did not return to levels associated with normal pregnancy. CONCLUSIONS: In women with pre-existing decreased platelet aggregation suggestive of platelet exhaustion, aspirin increased aggregation. This suggests that aspirin decreases in vivo platelet activation and thereby decreases the platelet exhaustion revealed by the in vitro studies.
No takes yet. Share an insight, caveat, or question.
Sullivan et al. (1993) conducted an observational in Pre-eclampsia (n=6). Aspirin vs. Baseline (prior to aspirin therapy) and normal pregnant women was evaluated on In vitro platelet aggregation in response to platelet-activating factor (PAF) and adenosine diphosphate (ADP). Aspirin therapy increased in vitro platelet aggregation in response to PAF and ADP in 6 pregnant women at risk of or with pre-eclampsia, compared to baseline.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: